GSK Pays $430M Upfront for CureVac’s COVID-19, Flu mRNA Vaccines

cafead

Administrator
Staff member
  • cafead   Jul 03, 2024 at 11:33: AM
via GSK on Wednesday announced it is restructuring an existing collaboration agreement with German biotech CureVac, focusing on their investigational mRNA vaccines for influenza and COVID-19 while withdrawing from other infectious disease projects.

article source